Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8794720 | Ophthalmology Retina | 2018 | 6 Pages |
Abstract
Intravitreal bevacizumab injection was effective in achieving complete or partial regression of CNVM in 73% of eyes with improved visual acuity and decreased subfoveal retinal thickness. Combined PDT and bevacizumab therapy led to further regression in eyes that had failed treatment with bevacizumab previously. Some cases of choroidal neovascularization associated with choroidal nevi did not seem to threaten the vision.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Metasebia T. MD, Hakan MD,